Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-17T16:14:57.390Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacokinetics and Therapeutic Efficacy of Haloperidol Decanoate after Loading Dose Administration

Published online by Cambridge University Press:  29 January 2018

H. De Cuyper ,
J. Bollen ,
H. M. van Praag  and
D. Verstraeten
H. De Cuyper*
Affiliation:
Academic Psychiatric Centre ‘Salve Mater’, Lovenjoel, near Leuven, Belgium
J. Bollen
Affiliation:
Psychiatric Centre ‘Sancta Maria’, St Truiden, Belgium
H. M. van Praag
Affiliation:
Department of Psychiatry, Albert Einstein College of Medicine/Montefiori Medical Centre, New York, USA
D. Verstraeten
Affiliation:
Coordinator of Scientific Research, Academic Psychiatric Centres, Leuven, Belgium
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

For this open study, we selected 21 chronic psychotic female in-patients (16 of them schizophrenics) who were being maintained on oral neuroleptics. After a wash-out period, they were treated by intramuscular depot injections of haloperidol decanoate, once a month for four months. The dose was calculated from the previous oral dosage, and the amount of the first injection was double that of the three following injections. Relatively stable plasma levels of haloperidol were achieved with the first injection, and corresponded to those observed with oral medication. A very significant correlation was found between plasma level and the dose administered, but not between plasma level and therapeutic effect. The clinical condition of about two-thirds of the patients remained unchanged or improved, compared with the period of oral treatment. During the first two months of treatment, there was more rigidity and tremor, but from the third month, the extrapyramidal symptoms were less pronounced than during the period of oral neuroleptics.

Type
Papers
Information
The British Journal of Psychiatry , Volume 148 , Issue 5 , May 1986 , pp. 560 - 566
Copyright
Copyright © 1986 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Deberdt, R., Elens, P., Berghmans, W., Heykants, J., Woestenborghs, R., Driesens, F., Reyntjens, A. & Van Wijngaarden, I. (1980) Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: Efficacy, dosage schedule and plasma levels. Acta Psychiatrica Scandinavica, 62, 356–363.Google Scholar
De Buck, R. P., Zelashi, N., Gilles, C., Durdu, J. & Braiman, H. (1981) Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data. Progress in Neuro-Psychopharmacology. 5, 499–502.CrossRefGoogle ScholarPubMed
Forsman, A. & Öhman, R. (1977) Applied pharmacokinetics of haloperidol in man. Current Therapeutic Research, 21, 396–411.Google Scholar
Gelders, Y. G., Reyntjens, A. J. M., Ash, C. W. & Aerts, T. J. L. (1982) 12-month study of haloperidol decanoate in chronic schizophrenic patients. International Pharmacopsychiatry, 17, 247–254.CrossRefGoogle ScholarPubMed
Heykants, J. J. P. & Gelders, Y. G. (1984) Haloperidol decanoate: pharmacokinetics in dogs and man. In Advances in Neuropsychopharmacology (ed. Burrows, G. D.). London: John Libbey.Google Scholar
Hollister, L. (1981) Clinical use of plasma concentrations of psychotherapeutic drugs: An overview. In Psychotropic Drugs. Plasma Concentrations and Clinical Response, (eds. Burrows, G. D. & Norman, T. D.) New York and Basel: Marcel Dekker.Google Scholar
Honigfeld, G., Gillis, R. D. & Klett, C. J. (1966) NOSIE-30: A treatment-sensitive ward behaviour scale. Psychological Reports, 19, 180–182.Google Scholar
Johnson, D. A. W. (1979) Clinical considerations in the use of depot neuroleptics for the treatment of schizophrenia. In: Management of Schizophrenia: Biological and Sociological Aspects, (ed. van Praag, H. M.). Assen: Van Gorcum.Google Scholar
Kirk, R. E. (1968) Experimental Design. Procedures for the Behavioural Sciences. Belmont, California: Brooks/Cole Publishing Company.Google Scholar
Niemegeers, C. J. E., Heykants, J. J. P. & Janssen, P. A. J. (1981) Anti-emetic effect of haloperidol in the dog as related to plasma level and dose. Psychopharmacology, 75, 240–244.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) Brief psychiatric rating scale (BPRS). Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Parent, M., Toussaint, C., Driesens, F. & Gelders, Y. (1981) Pharmacocinétique du décanoate d'halopéridol chez le psychotique. Acta Psychiatrica Belgica, 81, 399–405.Google Scholar
Reyntjens, A. J. M., Heykants, J. J. P., Woestenborghs, R. J. H., Gelders, Y. G. & Aerts, T. J. L. (1982) Pharmacokinetics of haloperidol decanoate: A 2-year follow-up. International Pharmacopsychiatry, 17, 238–246.Google Scholar
Rivera-Calimlim, L., Castaneda, L. & Lasagna, L. (1973) Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics, 14, 978–986.Google Scholar
Suy, E., Woestenborohs, R. & Heykants, J. (1982) Bioavailability and clinical effect of two different concentrations of haloperidol decanoate. Current Therapeutic Research, 31.6. 982–991.Google Scholar
Van Den Eeckhout, E., Belpaire, F. M., Bogaert, M. G. & De Moerloose, P. (1980) Radio-immunoassay of bromperidol and haloperidol in human and canine plasma. European Journal of Drug Metabolism and Pharmacokinetics, 5, 45–48.Google Scholar
Viukari, M., Salo, H., Lamminsivu, U. & Gordin, A. (1982) Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Ada Psychiatrica Scandinavica, 65, 301–308.Google Scholar
Wode-Helgodt, B., Borg, S., Fyro, B. & Sedvall, G. (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of clorpromazine. Acta Psychiatrica Scandinavica, 58, 149–173.CrossRefGoogle Scholar
Youssef, H. A. (1982) A one-year study of haloperidol decanoate in schizophrenic patients. Current Therapeutic Research, 31, 6, 976–981.Google Scholar
Zissis, N. P., Psaras, M. & Lyketsos, G. (1982) Haloperidol decanoate, a new long-acting antipsychotic in chronic schizophrenics: double-blind comparison with placebo. Current Therapeutic Research, 31.4, 650–655.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.